Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 83 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Oxymetazoline Clear all
Completed Phase 2 Interventional Results available

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

NCT01043185
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
AZD3355, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

NCT05995444
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults

NCT01745380
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Loma Linda, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

NCT01045083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, escitalopram, methylphenidate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT04966325
View directory record Official record
Conditions
Hyperuricemia, Gout, Qt Interval, Variation in
Interventions
LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

NCT02436759
View directory record Official record
Conditions
Acquired Blepharoptosis
Interventions
RVL-1201, RVL-1201 Vehicle Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Artesia, California • Newport Beach, California • Rancho Cordova, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

NCT01913002
View directory record Official record
Conditions
Healthy
Interventions
LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

NCT02508753
View directory record Official record
Conditions
Healthy
Interventions
CXA-101/tazobactam, Moxifloxacin, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 2, 2026, 3:20 PM EDT
Not listed Phase 2 Interventional

A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT02439125
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Eltoprazine HCl, Placebo
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

4-way Crossover QT Evaluation in Healthy Subjects

NCT03709927
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
ZTI-01, Moxifloxacin 400mg, Placebo IV
Drug · Other
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

NCT01787357
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg, Placebo (for Olodaterol (BI1744)l), Placebo (for Tiotropium)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811
View directory record Official record
Conditions
Sialorrhoea
Interventions
oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D
Drug
Lead sponsor
Orient Pharma Co., Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

NCT04983589
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine HCl, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 55 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Bakersfield, California • Glendale, California • Inglewood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

NCT03331042
View directory record Official record
Conditions
Transient Insomnia
Interventions
SM-1, D+Z, D+L, Placebo
Drug
Lead sponsor
Sequential Medicine Ltd
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

NCT03565887
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
9 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
36
States / cities
Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

NCT03592121
View directory record Official record
Conditions
Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer, Nipple Disorder, Neuropathy, Cancer of Breast
Interventions
AB-101, Placebo
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

NCT00736931
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam, levetiracetam, lorazepam, placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

NCT00562120
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Allegra, Allegra-D, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
19 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients

NCT01844830
View directory record Official record
Conditions
Anesthesia
Interventions
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Loma Linda, California • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

NCT01161472
View directory record Official record
Conditions
Healthy
Interventions
4mg fesoterodine, 8mg fesoterodine, alprazolam 1mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience

NCT07777965
View directory record Official record
Conditions
Healthy Non-dependent, Recreational Sedative Users
Interventions
Alprazolam (Xanax), Placebo, Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 2, 2026, 3:20 PM EDT